Skip to main content
. Author manuscript; available in PMC: 2012 Dec 19.
Published in final edited form as: Nat Clin Pract Oncol. 2008 Nov 18;6(1):53–58. doi: 10.1038/ncponc1278

Figure 2.

Figure 2

Whole-body PET and PET/CT images of [18F]FHBG biodistribution in a human, two hours after it’s intravenous injection. Two coronal slices are shown to illustrate activity within the liver, gall-bladder, intestines, kidney’s and bladder, which are organs involved with [18F]FHBG’s clearance from the body. Background activity in all other tissues is relatively low, due to the absence of HSV1-tk or HSV1-sr39tk expressing cells within the body of this human volunteer.